Halozyme Therapeutics Inc (HALO)

46.93 -0.39 (-0.82%) USD  |  NASDAQ  |  Dec 20, 16:00
46.95 +0.02 (+0.04%) After-Hours: 20:00
More

Halozyme Therapeutics Max Drawdown (5Y): 49.06% for Nov. 30, 2024

Max Drawdown (5Y) Chart

View Max Drawdown (5Y) for HALO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Max Drawdown (5Y) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

Max Drawdown Definition

View Max Drawdown Definition
Start Trial

Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.

Read full definition.

Max Drawdown (5Y) Range, Past 5 Years

View Max Drawdown (5Y) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Max Drawdown (5Y) Benchmarks

View Max Drawdown (5Y) Benchmarks
Start Trial
Lexicon Pharmaceuticals Inc 94.56%
Novavax Inc 98.82%
Kura Oncology Inc 81.79%
TransMedics Group Inc 73.69%
Pulmonx Corp --

Max Drawdown (5Y) Related Metrics

Alpha (5Y) 1.198
Beta (5Y) 1.226
Annualized Standard Deviation of Monthly Returns (5Y Lookback) 44.58%
Historical Sharpe Ratio (5Y) 0.3941
Historical Sortino (5Y) 0.7961
Monthly Value at Risk (VaR) 5% (5Y Lookback) 16.45%